# Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)

> **NCT01749540** · PHASE2 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 64 (actual)

## Conditions studied

- B-Thalassemia

## Interventions

- **DRUG:** luspatercept

## Key facts

- **NCT ID:** NCT01749540
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-28
- **Primary completion:** 2015-11-11
- **Final completion:** 2015-11-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01749540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01749540, "Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01749540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*